Researchers discovered the importance of an enzyme that promotes growth of certain lung cancers. Lung cancer is a ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Now that the year is underway and a new presidential administration is in place in Washington, let’s consider the environment ...

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...

Eli Lilly and Co.’s end last year to its PI3Kα inhibitor program didn’t mean the pharma player was giving up on the target – ...

Hopes were high for a rebound in capital-markets activity this year A few notable Health Care deals along with M&A in the ...

JonesResearch initiated coverage of OnKure Therapeutics (OKUR) with a Buy rating and $32 price target. The clinical stage precision oncology ...

The word on San Francisco’s famously hilly streets is that big pharma is ready to go shopping in 2025, following a flurry of ...

Meanwhile, Eli Lilly announced plans to acquire Scorpion Therapeutics’ STX-478, a P13K inhibitor which is in phase I trials ...

For instance, in the second-largest M&A deal announced so far this year, Eli Lilly has acquired Scorpion Therapeutics for $2.5bn. The deal is focused on Scorpion’s pipeline of precision cancer drugs, ...